8-K - NovoCure Ltd (0001645113) (Filer)
Published . Updated .
Key takeaways
- 8-K - NovoCure filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
- Exposed: NVCR
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K - NovoCure filed an 8-K with the SEC on Nov 9 (a notice of a material company event).
Directly affected
- NVCR NovoCure+1.2% 7d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that NovoCure belongs to, so it often moves with news about it.
- SYK Stryker+18.3% 30d
Stryker is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- MMM 3M+9.3% 30d
3M is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- BSX Boston Scientific-3.1% 30d
Boston Scientific is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- BDX Becton, Dickinson and+17.2% 30d
Becton, Dickinson and is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
- MDLN Medline+8.4% 17d
Medline is a peer of NovoCure in surgical and medical instruments and apparatus; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NVCR | -0.60% | +10.06% | base | after close | after close | after close | after close |
| XLV | -0.10% | +2.63% | base | after close | after close | after close | after close |
| SYK | -5.82% | +4.25% | base | after close | after close | after close | after close |
| MMM | -3.69% | +4.75% | base | after close | after close | after close | after close |
| BSX | +3.70% | +7.16% | base | after close | after close | after close | after close |
| BDX | -6.30% | -1.37% | base | after close | after close | after close | after close |
| MDLN | -15.16% | +1.85% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-09 AccNo: 0001645113-26-000085 Size: 151 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
How far NovoCure (NVCR) has moved since 9 Nov 2026
| Company | When | Move | Status |
|---|---|---|---|
| BDX | three days earlier | -1.37% | final price |
| BDX | five days earlier | -6.30% | final price |
| BSX | three days earlier | +7.16% | final price |
| BSX | five days earlier | +3.70% | final price |
| MDLN | three days earlier | +1.85% | final price |
| MDLN | five days earlier | -15.16% | final price |
| MMM | three days earlier | +4.75% | final price |
| MMM | five days earlier | -3.69% | final price |
| NovoCure (NVCR) | three days earlier | +10.06% | final price |
| NovoCure (NVCR) | five days earlier | -0.60% | final price |
| SYK | three days earlier | +4.25% | final price |
| SYK | five days earlier | -5.82% | final price |
| XLV | three days earlier | +2.63% | final price |
| XLV | five days earlier | -0.10% | final price |
Congressional trades in the stocks in this story
- Rep. Thomas H. Kean Jr sold Stryker (SYK), worth $1,001 - $15,000 on 30 Sep 2026. That is 40 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 45 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Stryker (SYK) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 59 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 9 Sep 2026. That is 61 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (jointly held), worth $50,001 - $100,000 on 4 Sep 2026. That is 66 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Boston Scientific (BSX) (held by a dependent child), worth $1,001 - $15,000 on 3 Sep 2026. That is 67 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K - NovoCure Ltd (0001645113) (Filer)”
Companies carried with this story
- NVCR NovoCure
In “8-K - NovoCure Ltd (0001645113) (Filer),” NovoCure (NVCR) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NVCR
How “8-K - NovoCure Ltd (0001645113) (Filer)” reaches NovoCure (NVCR)
“8-K - NovoCure Ltd (0001645113) (Filer)” (9 Nov 2026) reaches NovoCure (NVCR) through this story.
The link for NovoCure (NVCR) is this: SEC 8-K filing -> direct issuer disclosure -> NVCR
The price range for NovoCure (NVCR), and the dates in the story
NVCR traded between 11.91 and 14.95 across 7 sessions. The latest close on file is 13.27.
What the saved facts support for NovoCure (NVCR)
14 out of 100
“8-K - NovoCure Ltd (0001645113) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.